7,623
Participants
Start Date
October 31, 2022
Primary Completion Date
September 4, 2023
Study Completion Date
December 29, 2023
Recombinant two-component COVID-19 vaccine (CHO cell)
Before reconstitution: Lyophilized powder for reconstitution in single-use vials After reconstitution with BFA03 adjuvant: Milk-white solution with no visible foreign matter
Placebo
"Before reconstitution:~Lyophilized powder for reconstitution in single-use vials~After reconstitution with BFA03 adjuvant:~Milk-white solution with no visible foreign matter"
B.P. Koirala Institute of Health Sciences, Dharān
Aramil City Hospital, Aramil
LLC Medical Service solutions, Izhevsk
"'Federal State Budgetary Scientific Institution Russian Scientific Centre of Surgery named after academician B.V. Petrovsky", Moscow
"'Joint Stock Company Clinical and diagnostic center Euromedservice", Moscow
"State Regional Budgetary Institution of Healthcare Murmansk Regional Clinical Hospital named after P.A. Bayandin", Murmansk
LLC Professorskaya klinika, Perm
UZI 4D Clinic LLC, Pyatigorsk
Klinika Zvyezdnaya LLC, Saint Petersburg
"Limited Liability Company Sfera-Med", Saint Petersburg
Research Center Eco-safety, Saint Petersburg
Jiangsu Rec-Biotechnology Co., Ltd.
INDUSTRY